Forest Laboratories, Inc., et al. v. Teva Pharmaceuticals USA, Inc., et al., C.A. Nos. 14-121-LPS; 14-200-LPS;14-508-LPS; 14-686-LPS; 14-1058-LPS; 14-1271-LPS, January 5, 2016.
Stark, C.J.
The disputed technology relates to pharmaceutical formulations. The following terms were considered:
-
“a modified release solid oral dosage form”
-
“substantially contributing to the modification of the release”
-
“plasma memantine concentration profile”
-
“change in memantine concentration as a function of time ( dC/dT) that is less than 50% that of an immediate release dosage form comprising the same dose of memantine as the composition”
-
“change in plasma concentration as a function of time ( dC/dT) in a defined time period of 0 to 6 hours after administration ... that is less than about 50% of the dC/dT provided by the same quantity of an immediate release form of memantine in said defined time period”
-
“the dC/dT is measured between the time period of 0 to Tmax of the immediate release form of memantine”
-
“comprising an extended release formulation of 22.5 mg to 33. 75 mg memantine, or a pharmaceutically acceptable salt thereof”
